Aquestive Therapeutics spent the second quarter of 2026 fixing its balance sheet rather than moving its top line, and the quarter's headline number, a $22.9 million net loss, almost entirely reflects a one-time $11.7 million loss on extinguishment of debt tied to the May 12, 2026 refinancing of its 13.5% senior secured notes with a new $150 million Oaktree-led term loan facility, of which $55 million was drawn at closing. Strip that one charge out, and the second quarter core net loss was $11.2 million, narrower than the $13.5 million loss a year ago, on revenue that grew 38% to $13.8 million. The strategic narrative underneath the noise is straightforward: Aquestive is funding itself through the final twelve months before the FDA either approves or rejects its lead asset Anaphylm, a sublingual epinephrine film for type I allergic reactions, and management has now built the runway to get there. The second quarter check-up showed two favorable clinical signals (the human factors validation study and the pharmacokinetic study both met their primary endpoints, addressing the Complete Response Letter issued January 30, 2026), one favorable revenue signal (manufacture and supply revenue up 24% to $11.9 million on continued Indivior Suboxone demand and 48 million doses produced versus 37 million a year ago), and one favorable financing signal (a five-year, interest-only Oaktree facility with three additional tranches tied to FDA approval and a sales milestone).
The single most important observation is that Aquestive now has the capital structure, the regulatory de-risking progress, and the cash to attempt a self-commercialized launch of Anaphylm in the United States, with the New Drug Application (NDA) resubmission now committed to the third quarter of 2026 and the company continuing to position for a focused, allergist-led launch. The market is pricing AQST for the Anaphylm outcome, with a $4.29 share price as of August 17, 2026 implying a fully-diluted equity value of roughly $540 million against $98.5 million of cash and $50.7 million of long-term debt at quarter-end. Our interpretation is that the equity is currently priced for the FDA approval scenario to land but the launch-execution scenario to disappoint, a base case that the May 12 Oaktree refi and the human-factors data have materially reduced the probability of.
The load-bearing risk is execution, not approval. The Oaktree term loan carries a Tranche B ($20 million) drawable only after FDA approval of Anaphylm and a Tranche C ($25 million) tied to a 2027 net sales milestone, which means management must execute a launch into a competitive epinephrine rescue market where EpiPen and generic alternatives dominate. A favorable Complete Response Letter resubmission followed by a six-month FDA review with potential approval in the second quarter of 2027 is the central scenario; the central downside is a second Complete Response Letter or a label narrower than allergists can use, which would force a re-pivot toward outlicensing. The falsifiable clock is the third quarter of 2026 NDA resubmission event itself, the 2026 financial results call in March 2027 that reveals whether the human-factors validation data translated into a Complete Response Letter cleared and any FDA action, and the May 31, 2027 deadline by which the Anaphylm approval must land for the Tranche B draw to remain available under the Oaktree credit agreement.